Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet

Core Viewpoint - Arcturus Therapeutics (ARCT) has seen a 7.5% increase in share price over the past four weeks, closing at $12.81, with analysts suggesting a potential upside of 371.4% based on a mean price target of $60.38 [1][12]. Price Targets and Analyst Estimates - The mean price target is derived from eight short-term estimates, with a standard deviation of $33.97, indicating variability among analysts [2]. - The lowest price target of $32 suggests a 149.8% increase, while the highest target of $140 indicates a potential surge of 992.9% [2]. - A low standard deviation among price targets suggests a strong consensus among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates upward, which is a positive indicator for potential stock upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 42.1% over the past month, with four estimates rising and no negative revisions [12]. - ARCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them can be misleading, as they often do not accurately predict stock price movements [3][7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].